Sodium benzoate is under clinical development by SyneuRx International (Taiwan) and currently in Phase III for Schizophrenia. According to GlobalData, Phase III drugs for Schizophrenia have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Sodium benzoate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sodium benzoate overview

Sodium benzoate (SND-1, SB-01, SR-01) is under development for the treatment of adolescent schizophrenia, refractory schizophrenia, add-on therapy in schizophrenia and dementia.  It is administered through the oral route. It acts by targeting D-amino acid oxidase (DAAO).

SyneuRx International (Taiwan) overview

SyneuRx International (Taiwan) (SyneuRx International) is a bio-medical company that specializes in developing drugs for the treatment of central nervous system-related disorders. The company is headquartered in Taipei City, Taipei, Taiwan.

For a complete picture of Sodium benzoate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.